C
CVM
CEL-SCI Corp
2.740
+0.320+13.22%After Hours: 2.750 +0.010 +0.37%19:00 10/06 EDT
OPEN/PREV CLOSE2.420/2.420
TODAY RANGE2.290-2.830
VOL470.17K
MARKET CAP48.19M
52 WEEK RANGE0.8900-10.70
AVG VOL (3M)238.58K
% TURNOVER2.67%
TURNOVER--
P/E (TTM)-1.0212
% RANGE22.31%
EPS(TTM)-2.6830
P/E(FORWARD)-0.8925
P/B4.399
BVPS0.6229
DIVIDEND--
P/S159.87
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP46.41M
SHARES OUTSTANDING17.59M
NEXT EARNINGS12/28-01/01
FREE FLOAT16.94M
LOT SIZE1
EX-DATE05/20/2025
News
Press Releases
Financial Reports
Profile
TipRanks·09/15 12:46
CEL-SCI to deliver keynote at Otorhinolaryngology 2026
TipRanks·08/17 16:31
Midday Fly By: Equinor buys stake in Energy Center, Nvidia to invest $1.5B in SB
Seeking Alpha·08/17 13:16
Cel-Sci GAAP EPS of -$0.47
Benzinga·08/17 12:39
CEL-SCI Q3 EPS $(0.47) Up From $(1.36) YoY
Dow Jones·08/17 12:33
*CEL-SCI 3Q Research and Development Expenses $3.6M >CVM
Dow Jones·08/17 12:33
*CEL-SCI 3Q Loss/Shr 47c >CVM
Dow Jones·08/17 12:30
Press Release: CEL-SCI Reports Fiscal Third Quarter 2026 Results
TipRanks·08/04 12:18
CEL-SCI announces publication of study supporting multikine biomarker strategy
TipRanks·07/30 12:44
CEL-SCI announces manuscript on Phase 3 study to be published in Oral Oncology
Benzinga·07/16 17:05
12 Health Care Stocks Moving In Thursday's Intraday Session
TipRanks·07/13 12:10
CEL-SCI to launch FDA registration-enabling Phase 3 Confirmatory study
Benzinga·07/13 12:06
CEL-SCI To Launch Phase 3 Confirmatory Study
TipRanks·06/24 12:11
CEL-SCI, Saudi Amarox hold strategic agreement signing at BIO 2026
TipRanks·06/16 12:14
CEL-SCI highlights dual-track strategy for Multikine
Same Industry
Name/Symbol
Change%
Price